A Bold Step Forward in Nuclear Medicine
DOSIsoft just decided to throw down the gauntlet in the world of nuclear medicine by launching DOSIsoft Theranostics. Scheduled ahead of the SNMMI 2026, this new division is all about ramping up innovation in theranostics software. Seems they want to ditch any lingering ties to the old ways and fully immerse themselves in the nitty-gritty of personalized treatment through sophisticated software.
The New Kid on the Block: DOSIsoft Theranostics
This move to break away and form a focused entity is a real statement. DOSIsoft Theranostics ain't shackled to its parent company; it's got the freedom to chart its own course. They're ready to latch onto partnerships, dive into new investments, and bolster nuclear medicine practices that have been begging for a shot of fresh ideas.
Just imagine having the reins to accelerate the clinical and industrial adoption of theranostics. They're tapping into over two decades of DOSIsoft's know-how, pushing toward quantitative imaging, and AI-driven workflows. What they’re offering isn’t just software; it’s the evolution of nuclear medicine into something more patient-focused.
The Grand Plan with PLANET®
Let's get this straight—at the heart of this revolution is DOSIsoft's platform, PLANET®. This isn't some upstart platform; it's battle-tested across the globe, approved by both the FDA and CE, which is no small feat. We're talking about advanced voxel-based multi-radionuclide dosimetry and the kind of interoperability that gets radiopharmaceutical therapy experts excited.
The beauty of PLANET® is its vendor-neutral approach. It gives the medical pros the power to flex across varied workflows and therapeutic plans without missing a beat. If you've got a lineup of imaging modalities and departments shouting for attention, PLANET® can handle the noise and streamline it for patient care.
"Creating a dedicated theranostics organization reflects DOSIsoft's long-term commitment to this rapidly expanding field," said Marc Uszynski, CEO of DOSIsoft.
Heading to SNMMI 2026
Catch them at SNMMI 2026, booth #1358, showing the world what they've got. Expect them to showcase their vision and how they plan to tackle the challenges of personalized nuclear medicine. Partnering with research centers globally, DOSIsoft Theranostics is setting itself up to be more than just a player—they're going in as a leader.
Innovating for the Future
DOSIsoft's journey from a spin-off of prestigious institutions to leading the charge in dosimetry software is a lesson in commitment. With over 1,000 installations spanning 80 countries, this company knows how to push boundaries. As part of the European Thera4Care project, they're not sitting idly by—they’re actively contributing to shaping the theranostics ecosystem.
All in all, DOSIsoft Theranostics seems ready to drive nuclear medicine into a new era where treatments are more personalized than ever before. They’re aligning smartly with the future—talk about striking while the iron's hot.
